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Abstract
Introduction: Selecting women affected with breast cancer who are most likely to carry a germline mutation in
BRCA1 and applying the most appropriate test methodology remains challenging for cancer genetics services. We
sought to test the value of selecting women for BRCA1 mutation testing on the basis of family history and/or
breast tumour morphology criteria as well as the value of testing for large genomic alterations in BRCA1.
Methods: We studied women participating in the Breast Cancer Family Registry (BCFR), recruited via population-
based sampling, who had been diagnosed with breast cancer before the age of 40 years who had a strong family
history of breast or ovarian cancer (n = 187) and/or a first primary breast tumour with morphological features
consistent with carrying a BRCA1 germline mutation (n = 133; 37 met both criteria). An additional 184 women
diagnosed before the age of 40 years who had a strong family history of breast or ovarian cancer and who were
not known to carry a germline BRCA1 mutation were selected from among women who had been recruited into
the BCFR from clinical genetics services. These 467 women had been screened for BRCA1 germline mutations, and
we expanded this testing to include a screen for large genomic BRCA1 alterations using Multiplex Ligation-
dependent Probe Amplification.
Results: Twelve large genomic BRCA1 alterations were identified, including 10 (4%) of the 283 women selected
from among the population-based sample. In total, 18 (12%), 18 (19%) and 16 (43%) BRCA1 mutations were
identified in the population-based groups selected on the basis of family history only (n = 150), the group selected
on the basis of tumour morphology only (n = 96) and meeting both criteria (n = 37), respectively.
Conclusions: Large genomic alterations accounted for 19% of all BRCA1 mutations identified. This study
emphasises the value of combining information about family history, age at diagnosis and tumour morphology
when selecting women for germline BRCA1 mutation testing as well as including a screen for large genomic
alterations.
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Introduction
For many women with a personal and/or family history
of breast cancer, knowing that they carry a germline
mutation in a breast cancer predisposition gene can be
informative for their clinical management and that of
family members. However, mutations in currently
known breast cancer predisposition genes are very rare,
and the majority of women who undergo genetic testing
for these genes are not found to be carriers of mutations
(identifiable by current molecular methods).
It remains challenging but necessary for clinical genet-
ics services, and in some settings, insurers, to select
women most likely to carry a germline mutation in
BRCA1 and BRCA2 for genetic testing. Most tools used
for estimating a woman’s risk of carrying a mutation in
one of these genes are predominantly based on family
history. Even when accurately reported, well collected
and verified, family history is often not predictive of car-
rier status unless it is extreme, as family history is not
highly sensitive or specific to mutation status [1]. Recent
and current work have incorporated some details of the
associated breast cancer pathology into risk models, but
this effort has essentially been restricted to immunohis-
tochemical data such as estrogen receptor (ER), proges-
terone receptor (PR), HER2 and cytokeratin (CK5/6,
CK14) status [2-4].
It has been widely reported that some breast tumour
morphological features are associated with carrying a
BRCA1 mutation and that consideration of a few of
these features can identify almost all BRCA1 germline
mutation carriers among women with early-onset breast
cancer without taking into account family history [5-7].
The methodological approaches applied to identify
BRCA1 mutations also vary between clinical service
laboratories and can have an impact on the proportion
of women identified as carrying a mutation [8]. Most
currently applied methods are based on polymerase
chain reaction (PCR) assays and have moderate to high
specificity and sensitivity for identifying mutations invol-
ving one or a few nucleotides within defined, predomi-
nantly exonic regions. Analytical methods for
interpreting these nucleotide alterations are continuing
to improve [9,10]. However, short-fragment, PCR-based
analyses are usually insensitive to the detection of large
genomic alterations, and unless these specific tests are
applied such mutations are likely to be missed in a rou-
tine short-fragment PCR-based screening protocol.
The frequency of large genomic alterations varies
between populations, and this has become more apparent
as methods to detect such mutations have become more
robust and available [11]. Ticha et al. [12] reported that
12.3% of all BRCA1 mutations identified in the Czech
population are large genomic rearrangements. Similarly,
Agata et al. [13] reported that they could represent up to
one-third of BRCA1 mutations identified in the Italian
population. Reports from the Netherlands have demon-
strated that these types of mutations can account for 27%
to 36% of all BRCA1 mutations in the Dutch population
[14,15]. In addition to the effect of founder mutations,
some regions of BRCA1 seem to be implicated more fre-
quently in genomic alterations, such as the exon 1A-2
region [16]. The value of large genomic rearrangement
testing for many clinical genetics services remains unclear.
We sought to further investigate the value of using
family history and tumour morphologic features in
selecting women for BRCA1 mutation testing. We
applied two criteria (one for family history and one for
tumour morphological features) to select women partici-
pating in the Breast Cancer Family Registry (BCFR) who
had already undergone extensive BRCA1 mutation
screening [17]. This testing had not, however, included
routine testing for large genomic alterations in the
BRCA1 region, so we applied Multiplex Ligation-depen-
dent Probe Amplification (MLPA; MRC-Holland,
Amsterdam, the Netherlands) testing to determine the
proportion of BRCA1 mutations in the selected women
that could be attributed to mutations of this type.
Materials and methods
The Breast Cancer Family Registry
The BCFR was established in 1995 as an international
collaborative resource to facilitate research into the
genetic and environmental causes of breast cancer. The
BCFR has collected detailed epidemiological data, family
history information and biospecimens from over 13,000
families [18]. Relevant to this study are the incidence of
breast cancer cases and their relatives ascertained
through population-based cancer registries (population-
based case families) and families with strong cancer
histories of breast or ovarian cancer identified through
cancer family clinics and community outreach (clinic-
based families). Population-based families were recruited
in the San Francisco Bay Area, northern California, USA;
the Province of Ontario, Canada; and Melbourne and
Sydney, Australia. Clinic-based families were recruited in
Philadelphia, New York City and Utah, USA; the Pro-
vince of Ontario, Canada; and Melbourne and Sydney,
Australia. A proband is defined as the index case (identi-
fied from the relevant cancer registry) in population-
based families and as the youngest affected participating
female member of clinic-based families. All sites used
standardised questionnaires and protocols to collect
family history information, epidemiological and clinical
data, and biological specimens, with a strong emphasis
on quality control measures throughout the collection,
processing and storing of data and samples [17,18]. This
study was approved by the Human Research Ethics Com-
mittee of The University of Melbourne.
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BRCA1 and BRCA2 mutation testing
BCFR participants have undergone extensive testing for
BRCA1 and BRCA2 mutations using techniques
described previously [8,17,19], including two-dimensional
gel scanning, denaturing high-performance liquid chro-
matography, enzymatic mutation detection, single-strand
conformation polymorphism analysis and the protein
truncation test. Direct gene sequencing of both genes has
also been carried out by individual laboratories and Myr-
iad Genetics (Salt Lake City, UT, USA) [8,17,19]. Muta-
tion testing in other genes, such as ATM, TP53 and
CHEK2, has also been performed and reported elsewhere
[20-22]. The criteria used by the BCFR for defining dele-
terious mutations are the same as those used by the
Breast Cancer Information Core [23] and Myriad Genet-
ics. No screening was applied that specifically tested for
large genomic alterations in the BRCA1 gene. Some car-
riers of BRCA1 duplication exon 13 were identified by
specific PCR-based testing for the breakpoints [19,24]
and via RNA-based protein truncation testing [8].
Selection criteria
Women recruited through population-based sampling
Family history criteria We selected case probands who
were diagnosed with breast cancer before age 40 years
and had two or more first- or second-degree relatives
with breast or ovarian cancer.
Tumour morphology criteria We selected case pro-
bands whose tumour morphology was consistent with
carrying a BRCA1 mutation [7]. Case probands from the
Australian BCFR were selected if their breast tumours
had five or more of the following morphological features:
(1) mitotic index >50/10 high-power fields (HPF), (2)
malignant nuclear grade, (3) little or no tubule formation,
(4) a trabecular growth pattern, (5) pushing margins
(>50%), (6) a circumscribed growth pattern, (7) a syncy-
tial growth pattern, (8) necrosis and (9) moderate or
intense lymphocytic infiltrate [5,7]. From the Northern
California BCFR, we first selected all breast cancers that
had been scored as medullary or atypical medullary as
their primary or secondary histological type and then
reviewed the histological slides of these cases to identify
those that met the criteria described above [7]. From the
Ontario BCFR, we selected cases that had five or more of
the following features: (1) mitotic index >50/10 HPF, (2)
malignant nuclear grade, (3) little or no tubule formation,
(4) a syncytial growth pattern, (5) circumscribed borders,
(6) a moderate intense lymphocytic infiltrate and (7)
necrosis. The selection of case probands from popula-
tion-based registries was done without regard to their
known BRCA1 or BRCA2 mutation status.
Women enrolled through clinic-based recruitment
We selected the youngest affected member of clinic-
based families for this study if they had been diagnosed
with breast cancer before age 40 years and had two or
more first- or second-degree relatives with breast and/or
ovarian cancer. Probands were excluded if they were
already known to carry a BRCA1 or BRCA2 deleterious
mutation.
BRCA1 large genomic alteration testing by Multiplex
Ligation-dependent Probe Amplification
Testing for large genomic alterations was performed by
MLPA using the SALSA MLPA Kit P002B BRCA1
(MRC-Holland) as described by Schouten et al. [25].
Quantities of 50 to 100 ng per reaction of DNA
extracted from Guthrie card blood spots, peripheral
whole blood or a lymphoblastoid cell line were used. All
reactions were performed in duplicate on a Corbett
Palm-Cycler, Corbett Life Science, Mortlake, NSW, Aus-
tralia, and PCR fragments were analysed on an ABI
3730 DNA Analyser (Applied Biosystems, Foster City,
CA, USA).
Analysis of the fragment peak areas and visual exami-
nation of the MLPA histograms were performed to
identify large genomic alterations [26]. A normalised
value of 1.0 represents the detection of both exonic
alleles (that is, no alteration), a value ≤0.65 is the thresh-
old suggestive of loss of one exonic allele (that is, dele-
tion) and a value ≥1.3 suggests the gain of one or more
exonic alleles (that is, duplication). All cases with nor-
malised values ≤0.65 or ≥1.3 were repeated in an inde-
pendent molecular analysis. Large alterations were
verified using the SALSA MLPA Kit P087 BRCA1
(MRC-Holland). For P087 analysis, cases were compared
with BRCA1 mutation-negative controls. Cases that had
MLPA analysis suggestive of a single exon loss or gain
were sequenced to confirm that probe hybridization was
not being disrupted by genetic variation in the MLPA
probe hybridization regions.
Results
Screening of the population-based probands
Two hundred eighty-three probands from population-
based families were selected for this study. Of these pro-
bands, 150 met the family history only criteria, 96 met
the tumour morphology only criteria and 37 fulfilled
both criteria. BRCA1 and BRCA2 mutation testing had
already identified 15 BRCA1 mutation carriers in the
family history only group (15 of 150, or 10%), 14
BRCA1 mutation carriers in the morphology only group
(14 of 96, or 15%) and 12 BRCA1 mutation carriers in
the group who met both criteria (12 of 37, or 32%).
There were 17 BRCA2 mutation carriers who had been
identified in the family history only group (17 of 150, or
11%), one BRCA2 mutation carrier in the morphology
only group (1 of 96, or 1%) and four met both criteria
(4 of 37, or 11%) (see Table 1).
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Table 1 shows that MLPA analysis identified eight
case probands as carriers of large BRCA1 genomic
alterations. Two additional case probands were known
to have a BRCA1 exon 13 duplication that had been
identified by previous testing, and these are included in
Table 1. The BRCA1 large genomic alterations included
five single-exon deletions (exon 5, exon 17 and exon 20)
or duplications (exon 13) and five alterations involving
the deletion of multiple exons (exon 1A-2, exon 1A-17,
exon 1A-23 and exon 1A-24). An additional proband
was found to have an MLPA profile consistent with an
exon 13 deletion. However, Sanger sequencing of the
exon revealed a 1-bp deletion adjacent to the ligation
site of the P002 exon 13 probes. This mutation was
characterised as BRCA1 4362delG and is reported in the
“Other BRCA1 mutation” row in Table 1. The detection
of this mutation had been missed by prior two-dimen-
sional gel electrophoresis testing.
By combining the data from the screen for large geno-
mic alterations with the mutation information that had
been generated prior to this study using routine screening
methods [17], we identified 18 probands (12%) in the
family history only group carrying a deleterious BRCA1
mutation (3 probands, 2% carried large genomic altera-
tions), 18 probands (19%) in the tumour morphology only
group carrying a BRCA1 mutation (3 probands, 3% carried
large genomic alterations) and 16 probands (43%) in the
group meeting both criteria and carrying a BRCA1 muta-
tion (4 probands, 11% carried large genomic alterations)
(Table 1). Overall, 10 (19%) of the 52 BRCA1 mutations
found in these women were large genomic alterations.
As there were some differences in the methods used to
select cases that qualified for inclusion in the morphology
group across the population-based BCFRs (see Materials
and methods), the outcomes of the BRCA1 testing are
detailed both as overall findings and for each BCFR indi-
vidually (population-based samples) in Table 1.
Screening of probands recruited from clinical services
There were 184 case probands from the BCFR clinic
recruitment participants that met our study criteria
(excluding BRCA1 and BRCA2 mutation-carrying pro-
bands). MLPA screening identified a BRCA1 exon 22
deletion (reported previously) and a BRCA1 exons 14-20
deletion. Histological sections stained with haematoxylin
and eosin were available for review from the breast can-
cer carrying the BRCA1 exon 22 deletion, and this sec-
tion was found to meet the tumour morphology criteria
applied to the population-based probands in this study
(Table 2).
Table 1 Women recruited into BCFRs on the basis of population-based sampling who met the family history and
tumour morphology criteria of this studya
Mutation
status of
proband
Family history
only, 44/53/53b
(n = 150)
Family historyc,
63/57/67b
(n = 187)
Tumour
morphology only,
80/14/2b (n = 96)
Tumour
morphologyd, 99/
18/16b (n = 133)
Both family history and
tumour morphology, 19/4/
14b (n = 37)
Study total,
143/71/69b
(n = 283)
No identified
mutation, n
110 127 77 94 17 204
Identified
mutation, n
40 60 19 39 20 79
BRCA1
LGA, n
3 7 3 7 4 10
1/1/1b 3/3/1b 3/0/0b 5/2/0b 2/2/0b 6/3/1b
Other
BRCA1
mutation,
n
15 27 15e 27e 12 42
1/8/6b 8/9/10b 14/1/0b 21/2/4b 7/1/4b 22/10/10b
BRCA2
mutation,
n
17 21 1 5 4 22
ATM,
CHEK2,
TP53
mutations,
n
5 5 0 0 0 5
BRCA1
mutations, %
12 18 19 26 43 18
BRCA1 LGA, % 17 21 17 21 25 19
aBCFR, Breast Cancer Family Registry; LGA, large genomic alteration; ATM, ataxia telangiectasia mutated gene; CHEK2, CHK2 checkpoint homolog gene; TP53,
tumour protein 53 gene; bdata divided by BCFR (Australia/northern California/Ontario BCFRs); cincluding women who also met the tumour morphology criteria;
dincluding women who also met the family history criteria; eincluding BRCA1 4362delG identified by using Multiplex Ligation-dependent Probe Amplification
during this study.
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Table 2 shows the age at breast cancer diagnosis, the
details of the tumour morphology and the family history
details of the young women found to carry a large geno-
mic alteration in BRCA1 from both the population-
based and clinic-recruited families participating in the
BCFR. All 12 large genomic alterations in BRCA1
reported in this study were verified using the P087
MLPA Kit.
Discussion
Knowing that a woman with breast cancer carries a
germline BRCA1 mutation informs her clinical
Table 2 Details of BRCA1 large genomic alterations identified in this study
Sample Selection criteria (n) Large genomic BRCA1
alteration
Proband age at breast
cancer diagnosis, yr
Tumour
morphology
scorea
Family history
(age at diagnosis, yr)
Population-
based
Family history (150) Deletion exon 5 38 and 44 3 Breast, sister (42)
Ovarian, paternal aunt (44)
Ovarian, paternal
grandmother (60)
Deletion exon 1A-24 39 and 49 3 Breast, sister (53)
Ovarian, sister (40)
Ovarian, sister (50)
Duplication exon 13b 39 and 39 3 Breast, sister (33)
Breast, mother (49)
Breast, maternal
grandmother (62)
Breast, paternal
grandmother (49)
Tumour morphology (96) Deletion exon 20 31 and 35 7 Breast, paternal
grandmother (n.d.)
Deletion exon 1A-23c 33 5 Breast, paternal aunt (71)
Duplication exon 13b 36 9 Breast, mother (50)
Ovarian, mother (68)
Ovarian, paternal aunt (55)
Family history and tumour
morphology (37)
Deletion exon 17 31 7 Breast, maternal aunt (34)
Ovarian, maternal aunt (35)
Deletion exon 1A-2c 29 7 Breast, maternal aunt (30)
Breast, paternal aunt (52)
Ovarian, mother (56)
Deletion exon 1A-17 36 and 38 8 Breast, mother (53)
Ovarian, mother (62)
Breast, maternal
grandmother (84)
Ovarian, maternal
grandmother (n.d.)
Deletion exon 1A-23 34 7 Breast, mother (28)
Breast, maternal
grandmother (45)
Clinic-based Family history (184) Deletion exon 22 35 7 Breast, paternal aunt (23
and 24)
Ovarian, paternal aunt (49)
Deletion exons 14-20 36 n.d. Breast, sister (35)
Breast, mother (43)
Ovarian, maternal
grandmother (n.d.)
Total 467 12
aTumour morphology score is the total number of the following features that each breast cancer was recorded to display: 1, mitotic index >50/10 high-power
fields; 2, malignant nuclear grade; 3, little or no tubule formation; 4, a trabecular growth pattern; 5, pushing margins (>50%); 6, circumscribed growth pattern; 7,
a syncytial growth pattern; 8, necrosis; and 9, moderate or intense lymphocytic infiltrate; bBRCA1 exon 13 duplications were identified prior to this study;
cdescribed by Smith et al. [26]; n.d., age at diagnosis unknown (no data).
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management and that of her relatives. However, it
remains challenging for clinical genetics services to
select the women most likely to carry a germline muta-
tion in BRCA1 for genetic testing. Most tools used for
estimating a woman’s probability of carrying a BRCA1
mutation have been based predominantly on family his-
tory. Even when accurately reported, well-collected and
verified, is often unhelpful, except when the history is
extreme. That is family history is not highly sensitive or
specific to BRCA1 mutation status.
We have investigated the relative strengths of using
family history and tumour morphology, as well as
both criteria together, to select the women with early
onset breast cancer most likely to carry BRCA1 muta-
tions (including large genomic alterations) by using
the BCFR [18]. This resource provided many
strengths for the study: (1) it provided a large sample
size, with 467 women meeting one or more of the
study criteria; (2) significant germline mutation test-
ing had already been performed for BRCA1 and
BRCA2 [17] using validated methods [8]; (3) family
history of breast or ovarian cancer had been collected
from each case proband using a standardised, vali-
dated instrument (ensuring higher-quality data than
would likely have been collected from a similar num-
ber of women in a clinical setting) [18]; and (4)
tumour morphology had been reviewed for a propor-
tion of the breast cancers using a standardised, vali-
dated review form [7,27].
Prior to this study, 149 case probands (4%) who had
been recruited into the BCFR via population-based sam-
pling had been found to carry a BRCA1 mutation [17].
This is consistent with the frequencies reported in other
studies utilising this and similar population-based sam-
plings [28-30].
Using family history data collected in a standardised
fashion by the BCFR, we identified 187 women recruited
via population-based sampling who had a family history
at least as strong as two first- or second-degree relatives
with breast or ovarian cancer. Genetic testing of these
women identified 60 (32%) with a mutation in a breast
cancer susceptibility gene, 34 (18%) in BRCA1.
Using tumour morphology data collected by a stan-
dard pathology review of many of the breast cancers
arising in women participating in the Australian and
Ontario BCFRs, and by performing an extended review
of the medullary and atypical medullary type breast can-
cers in the northern California BCFR (see Materials and
methods), we identified 133 women whose tumour mor-
phology met our selection criteria and thus had many of
the morphological features consistent with being a
BRCA1 mutation carrier. Of these, 39 (29%) have now
been found to carry a germline mutation in a breast
cancer susceptibility gene, 34 (26%) in BRCA1.
The women who met both criteria composed the
group most enriched for BRCA1 mutation carriers
(43%). The proportion of large genomic alterations in
the total number of mutations identified was also
slightly higher in the women who met both the family
history and tumour morphology criteria (25%) compared
with the proportion in women who met only one of
these criteria (both 20%).
Similar work involving large genomic alterations in
BRCA2 could also be beneficial, but it is likely to have
less impact given current data which suggests there is a
broader morphological phenotype of breast cancers car-
rying these mutations and the extreme rarity of these
mutations in BRCA2 [31].
Conclusions
These results highlight the value of incorporating infor-
mation on family history and tumour morphology when
selecting women with the highest chance of carrying a
mutation in BRCA1 for mutation testing. This study
also shows that testing for large genomic alterations is
of value in this setting because 10 (19%) of the 52 muta-
tion carriers indentified in the groups of women selected
for this study carried large genomic alterations that were
identifiable by using MLPA.
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